BIO RAD LABORATORIES INC

Form 4

November 14, 2014

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction See Instruction See Instruction 30(h) of the Investment Company Act of 1940									PPROVAL 3235-0287 January 31, 2005 Everage rs per 0.5	
See Instru 1(b).	action				J					
(Print or Type I	Responses)									
]			2. Issuer Name and Ticker or Trading Symbol BIO RAD LABORATORIES INC [BIO, BIOB]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
	(First) (Middl AD LABORATORIF ALFRED NOBEL	(Month	3. Date of Earliest Transaction (Month/Day/Year) 11/13/2014				Director 10% Owner Officer (give title Other (specify below) Vice President and Treasurer			
HERCULES		If Amendment, Date Original iled(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State) (Zip)	Ta	ble I - Non-	Derivative	Secu	rities Acqu	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	(Month/Day/Year) Ex	Transaction Date 2A. Deemed execution Date, if any (Month/Day/Year)				ecquired ed of (D) (5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Bio-Rad A Common Stock	11/13/2014		M	1,000	A	\$ 57.49	3,496.7	D		
Bio-Rad A Common Stock	11/13/2014		M	1,500	A	\$ 62.47	4,996.7	D		
Bio-Rad A Common Stock	11/13/2014		S	1,261	D	\$ 111.92 (1)	3,735.7	D		

Edgar Filing: BIO RAD LABORATORIES INC - Form 4

Bio-Rad A \$ Common 11/13/2014 S 1,805 D 111.41 1,930.7 D Stock (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	\$ 57.49	11/13/2014		M	1,000	(3)	02/09/2015	Bio-Rad A Common Stock	1,00
Non-Qualified Stock Option (right to buy)	\$ 62.47	11/13/2014		M	1,500	<u>(4)</u>	04/03/2016	Bio-Rad A Common Stock	1,50

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

HUTTON RONALD W C/O BIO-RAD LABORATORIES, INC. 1000 ALFRED NOBEL DRIVE HERCULES, CA 94547

Vice President and Treasurer

Signatures

Ronald W. 11/14/2014 Hutton

Date

Reporting Owners 2

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$111.89 to \$111.94, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$111.39 to \$111.43, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (3) The option vested in five equal annual installments beginning on February 9, 2006.
- (4) The option vested in five equal annual installments beginning on April 3, 2007.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3